Tourmaline Bio, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
SCHEDULE 13G/A: RA Capital Exits Tourmaline Bio Stake, Now Holds 0%
RA Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in Tourmaline Bio, Inc., holding 0% of the common stock as of September 30, 2025.
SCHEDULE 13G/A: BlackRock Boosts Stake in Tourmaline Bio to 5.5%
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.5% beneficial ownership stake in Tourmaline Bio, Inc.'s common stock.
SCHEDULE 13G/A: QVT Financial Boosts Tourmaline Bio Stake to 8.39%
QVT Financial LP has reported an 8.39% beneficial ownership stake in Tourmaline Bio, Inc., holding 2,154,653 shares of common stock.
Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a 9.95% beneficial ownership stake in Tourmaline Bio, Inc. for investment purposes.
QVT Financial LP has filed a Schedule 13G, reporting a beneficial ownership of 5.74% of Tourmaline Bio, Inc.'s common stock as of March 31, 2025.
Blue Owl Capital Holdings LP has filed an amended Schedule 13G, reporting a 4.2% passive beneficial ownership stake in Tourmaline Bio, Inc. as of December 31, 2024.